SCHEMBL9932870

SCHEMBL9932870

CC1(C)c2ccccc2-c2c1cc(O)c1c(F)cc(F)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 7/20 0.35
PGR P06401 3/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MLNR O43193 1/20 0.31
NR1I2 O75469 1/20 0.31
CHRM2 P08172 1/20 0.31
ADRB1 P08588 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA2A P08913 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
CHRM3 P20309 1/20 0.31
DRD1 P21728 1/20 0.31
SLC6A2 P23975 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9940214 0.85 MAOA (0.31)
SCHEMBL9933463 0.81 PDK2 (0.34) PDK2MEN1KMT2AHTR1AHTR2A
SCHEMBL16713272 0.80 KDM4E (0.35) PDK2KDM4E
SCHEMBL9932470 0.79 PGR (0.33) PDK2PGRMEN1KMT2ACHRM2
SCHEMBL9934120 0.78 PDK2 (0.40) PDK2PGRMLNRNR1I2CHRM2
SCHEMBL164745 0.76 LMNA (0.39) PDK2MEN1KMT2AMLNRNR1I2
SCHEMBL29664335 0.76 ESR1 (0.33) PDK2MLNRNR1I2CHRM2ADRB1
SCHEMBL9929735 0.76 ESR1 (0.33) PDK2MLNRNR1I2CHRM2ADRB1
SCHEMBL9971715 0.72 PPARG (0.44) PDK2MEN1KMT2AKDM4EESR1
SCHEMBL720632 0.70 PDK2 (0.38) PDK2PGRMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073838-B2 Method of making indeno-fused naphthol materials TRANSITIONS OPTICAL, INC. (US) 2015-07-07 US disclosed
US-9073838-B2 Method of making indeno-fused naphthol materials TRANSITIONS OPTICAL, INC. (US) 2015-07-07 US disclosed
US-9073838-B2 Method of making indeno-fused naphthol materials TRANSITIONS OPTICAL, INC. (US) 2015-07-07 US disclosed
US-20140364618-A1 Method of Making Indeno-Fused Naphthol Materials TRANSITIONS OPTICALS, INC. (US) 2014-12-11 US disclosed
US-20140364618-A1 Method of Making Indeno-Fused Naphthol Materials TRANSITIONS OPTICALS, INC. (US) 2014-12-11 US disclosed
US-20140364618-A1 Method of Making Indeno-Fused Naphthol Materials TRANSITIONS OPTICALS, INC. (US) 2014-12-11 US disclosed
US-8765978-B2 Method of making indeno-fused naphthol materials TRANSITIONS OPTICAL, INC. (US) 2014-07-01 US disclosed
US-20120157696-A1 METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed
WO-2012082837-A1 METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 WO disclosed
WO-2012082837-A1 METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 WO disclosed
US-20120157696-A1 METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed
US-20120157696-A1 METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364618-A1 Method of Making Indeno-Fused Naphthol Materials IDH3A, NQO1, IDH3B PDK2 714/4885PGR 128/4885MEN1 595/4885
US-20120157696-A1 METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS NQO1, IDH3A, IDH2 PDK2 559/4885PGR 263/4885MEN1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.